

01 October 2024

Intra-Vitreous Injections or Implants

The Trust has recently moved to Electronic Record System which has had a temporary impact on the reporting mechanisms available for this information. We have provided the figures from 1 May 2024 to 5 June 2024 via our previous systems. The Information from 6 June 2024 to 31 August 2024 is via the new Electronic Record System which does not provide the same level of data at this point. We will be able to provide this information in future requests.

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2024:

Aflibercept	3879	
Bevacizumab – Avastin	6	
Bevacizumab – Biosimilar	0	
Brolucizumab	0	
Dexamethasone	51	
Faricimab	1331	
Fluocinolone acetonide	9	
Ranibizumab - Lucentis (pre-filled syringes)	607	
Ranibizumab - Lucentis (vials)	0	
Ranibizumab – Ongavia	0	
Ranibizumab – Ximluci	0	

2. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2024:

Number of Injections/Implants: May to August 2024:

Medisoft figures 01/05/24 – 05/06/24

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	1489	234	397
Bevacizumab	0	0	0
Dexamethasone	1	10	14
Faricimab	460	266	2
Ranibizumab - Lucentis	260	23	32
Ranibizumab - Ongavia	0	0	0
Ranibizumab - Ximluci	0	0	0

01 October 2024

Encompass injection figures 06/06/24- 31/08/24

Treatment	Total
Aflibercept	1759
Bevacizumab	6
Dexamethasone	26
Faricimab	603
Ranibizumab - Lucentis	292
Ranibizumab - Ongavia	0
Ranibizumab - Ximluci	0